Presentation is loading. Please wait.

Presentation is loading. Please wait.

Influence of insulin on AdipoR1 mRNA expression in murine C2C12 myotubes. Influence of insulin on AdipoR1 mRNA expression in murine C2C12 myotubes. Data.

Published byDana Paul Modified over 5 years ago

Similar presentations

Presentation on theme: "Influence of insulin on AdipoR1 mRNA expression in murine C2C12 myotubes. Influence of insulin on AdipoR1 mRNA expression in murine C2C12 myotubes. Data."— Presentation transcript:

1 Influence of insulin on AdipoR1 mRNA expression in murine C2C12 myotubes.
Influence of insulin on AdipoR1 mRNA expression in murine C2C12 myotubes. Data are presented as means ± SE of four independent experiments (n = 4) (1 AU = 1 ag/100 ng total RNA). A: Dose-response curve: in vitro–differentiated myotubes were incubated for 48 h with different insulin concentrations (0–100 nmol/l). B: Time course: in vitro–differentiated myotubes were treated for different time intervals (0–48 h) with 100 nmol/l insulin. Inset: Hexokinase II mRNA expression before and after 10 h of insulin (100 nmol/l) treatment. *Significantly different from 0 h (P = , Mann-Whitney rank-sum test). Harald Staiger et al. Diabetes 2004;53: ©2004 by American Diabetes Association

Download ppt "Influence of insulin on AdipoR1 mRNA expression in murine C2C12 myotubes. Influence of insulin on AdipoR1 mRNA expression in murine C2C12 myotubes. Data."

Similar presentations

Cardiorenal Med 2016;6: DOI: /

Cardiorenal Med 2016;6: DOI: /
IL-1β stimulates CXCL5 and CXCL8 gene expression and protein secretion in A549 cells in a time- and dose-dependent manner. IL-1β stimulates CXCL5 and CXCL8.

IL-1β stimulates CXCL5 and CXCL8 gene expression and protein secretion in A549 cells in a time- and dose-dependent manner. IL-1β stimulates CXCL5 and CXCL8.
Fig. 4 Topical application of SAAP-148 ointment eradicates acute and established infections of MRSA and A. baumannii from the skin. Topical application.

Fig. 4 Topical application of SAAP-148 ointment eradicates acute and established infections of MRSA and A. baumannii from the skin. Topical application.
Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.

Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.
Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.
Genetic and pharmacologic inactivation of KSR1 radiosensitizes A431 cells in vitro to the lethal effect of ionizing radiation. Genetic and pharmacologic.

Genetic and pharmacologic inactivation of KSR1 radiosensitizes A431 cells in vitro to the lethal effect of ionizing radiation. Genetic and pharmacologic.
Quantitation of Hsp-72 mRNA in human muscle biopsies and heat-shocked NIH-3T3 cells, using competitive RT-PCR. Quantitation of Hsp-72 mRNA in human muscle.

Quantitation of Hsp-72 mRNA in human muscle biopsies and heat-shocked NIH-3T3 cells, using competitive RT-PCR. Quantitation of Hsp-72 mRNA in human muscle.
Effects of insulin administration in streptozotocin-treated mice.

Effects of insulin administration in streptozotocin-treated mice.
Drug levels during the course of a dosing interval.

Drug levels during the course of a dosing interval.
Effect of insulin on hepcidin expression in HepG2 cells.

Effect of insulin on hepcidin expression in HepG2 cells.
Comparison of the protective effects of R and S isomers of LA on insulin-stimulated 2-DG uptake. Comparison of the protective effects of R and S isomers.

Comparison of the protective effects of R and S isomers of LA on insulin-stimulated 2-DG uptake. Comparison of the protective effects of R and S isomers.
Therapy-induced senescence of primary cells.

Therapy-induced senescence of primary cells.
MMAE resistance and intracellular accumulation.

MMAE resistance and intracellular accumulation.
Glucose, insulin, and AGE levels during an OGC before and after RT

Glucose, insulin, and AGE levels during an OGC before and after RT
Correlation between muscle Hsp-72 mRNA expression and rates of glucose and lipid turnover, as determined in protocol 2 (n = 36). Correlation between muscle.

Correlation between muscle Hsp-72 mRNA expression and rates of glucose and lipid turnover, as determined in protocol 2 (n = 36). Correlation between muscle.
Decreased GLP-1 receptor expression in islets after exposure to high glucose. Decreased GLP-1 receptor expression in islets after exposure to high glucose.

Decreased GLP-1 receptor expression in islets after exposure to high glucose. Decreased GLP-1 receptor expression in islets after exposure to high glucose.
Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.

Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.
Activation of β-adrenoceptors improves glucose tolerance in diabetic animals and increases glucose uptake in vivo, ex vivo, and in vitro. Activation of.

Activation of β-adrenoceptors improves glucose tolerance in diabetic animals and increases glucose uptake in vivo, ex vivo, and in vitro. Activation of.
Expression of SENP2 mRNA is regulated by palmitate-induced NF-κB activation. Expression of SENP2 mRNA is regulated by palmitate-induced NF-κB activation.

Expression of SENP2 mRNA is regulated by palmitate-induced NF-κB activation. Expression of SENP2 mRNA is regulated by palmitate-induced NF-κB activation.
The incidence of insulin-treated type 1 diabetes in the first 35 years of life. The incidence of insulin-treated type 1 diabetes in the first 35 years.

The incidence of insulin-treated type 1 diabetes in the first 35 years of life. The incidence of insulin-treated type 1 diabetes in the first 35 years.

Similar presentations

Ads by Google